Diadexus, Inc. Share Price

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/21/17	Diadexus, Inc. Went Out of Business	CI
08/18/08	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2T 42.4T 39.75T 36.29T 68.36T 47.02L 68.57T 5L 2L 23.74L 2L 2L 78.71L	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	52.9L 45.59L 42.74L 39.02L 73.5L 51Cr 73.73L 5.07Cr 1.98Cr 26Cr 1.99Cr 1.94Cr 85Cr	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/21/17	Diadexus, Inc. Went Out of Business	CI
08/18/08	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/18/09	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/16/01	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/16/29	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/16/29	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/16/20	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/16/07	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/16/07	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/16/13	Diadexus, Inc. Filed for Bankruptcy	CI
10/16/10	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/16/23	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/16/30	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ULTRAGENYX PHARMACEUTICAL INC.	-1.85%	+0.08%	-14.69%	-29.53%	258.11Cr
SAREPTA THERAPEUTICS, INC.	-1.99%	+12.88%	+15.65%	-82.12%	228.05Cr
BIONOTE, INC.	+1.05%	-0.83%	-14.59%	-3.32%	35Cr
DK LIFE SCIENCE CO., LTD.	+1.79%	+2.24%	-46.42%	-	5.19Cr
Average	-0.19%	+2.94%	-15.01%	-38.32%	105.23Cr
Weighted average by Cap.	-1.65%	+6.98%	-1.84%	-50.80%

	2014	2015
Net sales	2.61Cr 2.25Cr 2.11Cr 1.93Cr 3.63Cr 249.56Cr 3.64Cr 25Cr 9.77Cr 125.98Cr 9.8Cr 9.59Cr 417.72Cr	1.79Cr 1.54Cr 1.44Cr 1.32Cr 2.48Cr 170.92Cr 2.49Cr 17Cr 6.69Cr 86Cr 6.71Cr 6.57Cr 286.1Cr
Net income	-84.67L -72.96L -68.41L -62.45L -1.18Cr -81Cr -1.18Cr -8.12Cr -3.17Cr -41Cr -3.18Cr -3.11Cr -135.45Cr	-71.66L -61.75L -57.9L -52.85L -99.56L -68Cr -99.88L -6.87Cr -2.68Cr -35Cr -2.69Cr -2.63Cr -114.64Cr
Net Debt	-2L -2L -2L -1L -3L -1.89Cr -3L -18.98L -7L -95.53L -7L -7L -3.17Cr	52.41L 45.16L 42.34L 38.65L 72.82L 50Cr 73.05L 5.02Cr 1.96Cr 25Cr 1.97Cr 1.92Cr 84Cr

Diadexus, Inc. Share Price

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation : Diadexus, Inc.

Latest news : Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile